CN106620498A - Preparation method, quality control and use of traditional Chinese medicine composition for treating postinfectious cough - Google Patents
Preparation method, quality control and use of traditional Chinese medicine composition for treating postinfectious cough Download PDFInfo
- Publication number
- CN106620498A CN106620498A CN201510708038.9A CN201510708038A CN106620498A CN 106620498 A CN106620498 A CN 106620498A CN 201510708038 A CN201510708038 A CN 201510708038A CN 106620498 A CN106620498 A CN 106620498A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- chinese
- ethanol
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 132
- 239000000203 mixture Substances 0.000 title claims abstract description 117
- 238000002360 preparation method Methods 0.000 title claims abstract description 65
- 206010011224 Cough Diseases 0.000 title claims abstract description 50
- 238000003908 quality control method Methods 0.000 title claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 220
- 239000000463 material Substances 0.000 claims abstract description 82
- 239000000341 volatile oil Substances 0.000 claims abstract description 65
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000000284 extract Substances 0.000 claims abstract description 41
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 38
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 38
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 38
- 238000000605 extraction Methods 0.000 claims abstract description 38
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 38
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 34
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 34
- 235000013976 turmeric Nutrition 0.000 claims abstract description 34
- 238000001256 steam distillation Methods 0.000 claims abstract description 32
- 239000012452 mother liquor Substances 0.000 claims abstract description 31
- 239000000706 filtrate Substances 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 239000006228 supernatant Substances 0.000 claims abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 239000002552 dosage form Substances 0.000 claims abstract description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 8
- 208000013116 chronic cough Diseases 0.000 claims abstract description 4
- 208000015181 infectious disease Diseases 0.000 claims abstract description 4
- 230000002458 infectious effect Effects 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 129
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 76
- 238000012360 testing method Methods 0.000 claims description 59
- 239000013558 reference substance Substances 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 49
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 48
- 239000007788 liquid Substances 0.000 claims description 42
- 239000003208 petroleum Substances 0.000 claims description 30
- 239000007921 spray Substances 0.000 claims description 30
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims description 29
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims description 29
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims description 29
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims description 29
- 229940100243 oleanolic acid Drugs 0.000 claims description 29
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 20
- 238000010992 reflux Methods 0.000 claims description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 14
- 238000000079 presaturation Methods 0.000 claims description 14
- 238000004809 thin layer chromatography Methods 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 claims description 11
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 10
- RKFAZBXYICVSKP-AATRIKPKSA-N alpha-asarone Chemical compound COC1=CC(OC)=C(\C=C\C)C=C1OC RKFAZBXYICVSKP-AATRIKPKSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229940013618 stevioside Drugs 0.000 claims description 10
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 10
- 235000019202 steviosides Nutrition 0.000 claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims description 9
- 239000001116 FEMA 4028 Substances 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 9
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 9
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 9
- 229960004853 betadex Drugs 0.000 claims description 9
- 239000006189 buccal tablet Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000002398 materia medica Substances 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 239000007919 dispersible tablet Substances 0.000 claims description 6
- 239000007902 hard capsule Substances 0.000 claims description 6
- 239000007935 oral tablet Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 6
- 239000004299 sodium benzoate Substances 0.000 claims description 6
- 235000010234 sodium benzoate Nutrition 0.000 claims description 6
- 239000007901 soft capsule Substances 0.000 claims description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- 244000000231 Sesamum indicum Species 0.000 claims description 5
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 229940046011 buccal tablet Drugs 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 238000010812 external standard method Methods 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 4
- 238000011002 quantification Methods 0.000 claims description 4
- 235000020374 simple syrup Nutrition 0.000 claims description 4
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 4
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical group O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims 36
- 244000001632 Acorus gramineus Species 0.000 claims 17
- 235000013073 Acorus gramineus Nutrition 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 17
- 241000601164 Clematis orientalis Species 0.000 claims 14
- 239000012467 final product Substances 0.000 claims 9
- 230000006837 decompression Effects 0.000 claims 7
- 238000011161 development Methods 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 238000005057 refrigeration Methods 0.000 claims 6
- 238000002604 ultrasonography Methods 0.000 claims 6
- 238000004064 recycling Methods 0.000 claims 5
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 claims 4
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 claims 4
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 claims 4
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 229940096978 oral tablet Drugs 0.000 claims 3
- 239000000377 silicon dioxide Substances 0.000 claims 3
- 229950005162 benexate Drugs 0.000 claims 2
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 238000003672 processing method Methods 0.000 claims 2
- 239000000344 soap Substances 0.000 claims 2
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 claims 2
- 241000446313 Lamella Species 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 claims 1
- 238000012850 discrimination method Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 235000020985 whole grains Nutrition 0.000 claims 1
- 241000218158 Clematis Species 0.000 abstract description 33
- 239000003921 oil Substances 0.000 abstract description 23
- 235000014375 Curcuma Nutrition 0.000 abstract description 16
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract description 16
- 244000205574 Acorus calamus Species 0.000 abstract description 11
- 235000011996 Calamus deerratus Nutrition 0.000 abstract description 10
- 239000002994 raw material Substances 0.000 abstract description 8
- 239000000243 solution Substances 0.000 description 47
- 210000004072 lung Anatomy 0.000 description 21
- 239000012085 test solution Substances 0.000 description 20
- 229930185042 hederasaponin Natural products 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 235000006679 Mentha X verticillata Nutrition 0.000 description 11
- 235000002899 Mentha suaveolens Nutrition 0.000 description 11
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 235000008504 concentrate Nutrition 0.000 description 7
- 238000003809 water extraction Methods 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000002791 soaking Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 102000011759 adducin Human genes 0.000 description 4
- 108010076723 adducin Proteins 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000012088 reference solution Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002525 ultrasonication Methods 0.000 description 3
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 3
- 235000012141 vanillin Nutrition 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241001256368 Clematis chinensis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- -1 filter Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 241000209495 Acorus Species 0.000 description 1
- 235000006480 Acorus calamus Nutrition 0.000 description 1
- 241000544682 Acorus tatarinowii Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000903946 Clematidis Species 0.000 description 1
- 241000725146 Clematis hexapetala Species 0.000 description 1
- 241000915582 Clematis manshurica Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000963421 Curcuma kwangsiensis Species 0.000 description 1
- 235000003397 Curcuma kwangsiensis Nutrition 0.000 description 1
- 240000005629 Curcuma phaeocaulis Species 0.000 description 1
- 235000003391 Curcuma phaeocaulis Nutrition 0.000 description 1
- 241000963390 Curcuma wenyujin Species 0.000 description 1
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910002055 micronized silica Inorganic materials 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000009111 xianzhong Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种治疗感冒后咳嗽的中药组合物,是由以下重量份的原料药组成:威灵仙6‑20克、郁金6‑20克、石菖蒲3‑10克、薄荷3‑6克。制法:威灵仙、薄荷、石菖蒲及郁金药材,加入药材总量6‑12倍水,以水蒸气蒸馏法提取挥发油5‑9小时,收集挥发油,加入吐温‑80增溶或乙醇溶解,备用;将水蒸气蒸馏提取液过滤,得提油母液和滤渣;滤渣加入6‑10倍水煎煮1‑3次,每次1‑3小时,合并煎煮液与提油母液,将上清液浓缩后加75‑95%乙醇使含醇量达65‑85%,冷藏静置后取出,滤过,滤液减压回收乙醇至无醇味;加入增溶后的挥发油以及常规药用辅料,采用中药药剂学中常规的制剂方法,制成适宜剂型。本发明还提供了该中药组合物在制备治疗感染性咳嗽、各类慢性咳嗽药物中的应用。The invention provides a traditional Chinese medicine composition for treating cough after a cold, which is composed of the following raw materials in parts by weight: 6-20 grams of Clematis, 6-20 grams of Curcuma, 3-10 grams of Shichangpu, and 3-6 grams of Peppermint gram. Preparation method: Clematis clematis, peppermint, calamus and turmeric medicinal materials, add 6-12 times the total amount of medicinal materials with water, extract volatile oil by steam distillation for 5-9 hours, collect volatile oil, add Tween-80 to solubilize or ethanol Dissolve and set aside; filter the extract by steam distillation to obtain oil extraction mother liquor and filter residue; add 6-10 times water to the filter residue and decoct 1-3 times, each time for 1-3 hours, combine the decoction and oil extraction mother liquor, and After the supernatant is concentrated, add 75-95% ethanol to make the alcohol content reach 65-85%, take it out after refrigerating and standing still, filter, and recover the ethanol from the filtrate under reduced pressure until it has no alcohol smell; add the solubilized volatile oil and conventional medicinal The excipients are made into suitable dosage forms by conventional preparation methods in traditional Chinese medicine pharmacy. The invention also provides the application of the traditional Chinese medicine composition in the preparation of medicines for treating infectious cough and various chronic coughs.
Description
技术领域 technical field
本发明属于中药领域,涉及一种中药组合物,具体涉及一种治疗感冒后咳嗽的中药组合物及其制备方法与用途。 The invention belongs to the field of traditional Chinese medicines and relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating post-cold cough and its preparation method and application.
背景技术 Background technique
感冒又称为急性上呼吸道感染,是人类最常见的感染性疾病之一,成人平均每年感冒2-4次,而急性咳嗽是感冒伴随的最常见症状,是初级医疗保健机构就诊的最常见症状之一。 Cold, also known as acute upper respiratory tract infection, is one of the most common infectious diseases in humans. Adults have an average of 2-4 colds per year. Acute cough is the most common symptom associated with cold and the most common symptom in primary healthcare institutions. one.
据统计,每年大约11%-25%的患者会发生感冒后咳嗽(PIC),在流行季节,感冒后咳嗽发生率可高达25%-50%,此类人群当感冒本身急性期症状消失后,咳嗽仍然迁延不愈,多表现为刺激性干咳或咳少量白色黏液痰,可以持续数周,甚至更长时间频繁剧烈的咳嗽常常严重影响患者的学习、工作和生活,对人们的正常生活有较强负面影响,而中医药治疗本病具有一定优势。 According to statistics, about 11%-25% of patients experience post-influenza cough (PIC) every year. The cough is still protracted, mostly manifested as irritating dry cough or coughing a small amount of white mucus sputum, which can last for several weeks, or even longer. Strong negative impact, while traditional Chinese medicine treatment of this disease has certain advantages.
PIC属于中医学“外感咳嗽病”范畴。中医学认为肺主气,司呼吸,上连气道,开窍于鼻,咽喉为其门户,不耐寒热,易被邪侵。外感六淫之邪,又以风邪为先导,同时可夹杂寒、热、燥、湿等,未能及时表散,或止咳化痰药杂投、或苦寒清热药盲目使用、或敛肺收涩药误用,致外邪留恋,内伏于肺,肺失宣降,上逆而咳,所以感冒后咳嗽的中医证候特点之一为表邪未尽。 PIC belongs to the category of "exogenous cough disease" in traditional Chinese medicine. Traditional Chinese medicine believes that the lung governs qi, governs breathing, connects the airway, opens to the nose, and the throat is its portal. It is not resistant to cold and heat, and is easily invaded by evils. Exogenous pathogenic factors of the six evils, led by wind pathogens, may be mixed with cold, heat, dryness, dampness, etc., which cannot be dispersed in time, or miscellaneous cough and phlegm drugs, or blind use of bitter cold and heat-clearing drugs, or astringent lungs Misuse of astringent medicines can cause exogenous pathogens to linger, and the lungs lie in the lungs, and the lungs fail to ventilate and descend, leading to coughing. Therefore, one of the TCM syndrome characteristics of cough after a cold is that the external pathogens are not exhausted.
PIC的另一个特点为正虚邪恋,病情缠绵。感冒后咳嗽日久不愈,可转变成内伤咳嗽。《素问·咳论》中则指出“五脏六腑皆令人咳,非独肺也。”除了肺咳之外,尚有心咳、肝咳、脾咳、肾咳等,此时咳嗽病程长、病位深,则更为难治。关秋红等认为调补失宜也是感冒后咳嗽常见病因,过补或饮食失宜,内伤脾胃,水湿内停,上贮于肺,肺气肃降不利而咳。有的认为本病多因风热犯肺,暴怒伤肝,情伤日久,气机失常,复感外邪,化热炽津;或元阴亏损,无根之火,游行无制,客于咽喉所致。另有认为该病乃因肝气郁结、脾失健运、胃气虚弱,以致津液不能上承咽喉而致。也有很多医家从病理产物方面论治,主张从痰瘀论治,认为慢性咽炎发病过程中,“痰”和“瘀”是最常见的病理因素,而且痰瘀是相互并存的。有研究将将PIC分为5型:风邪恋肺型治以祛邪为主,寒饮伏肺型治以温肺化饮散寒,痰热蕴肺型治以清肺化痰为主,肝火犯肺则清肺止咳、柔肝缓急,肺脾气虚型则以补益肺脾为主。《中医临床诊疗术语证候部分》则将感冒后咳嗽分为阴虚内热型、气虚痰湿型、肝郁气滞型3型。 Another feature of PIC is love between righteousness and evil, and lingering illness. Cough after a cold does not heal for a long time, and can turn into internal injury cough. "Su Wen·Cough Theory" pointed out that "all internal organs and six internal organs make people cough, not only the lung." In addition to lung cough, there are also heart cough, liver cough, spleen cough, kidney cough, etc. At this time, the cough is long and sick. The deeper the bit, the more difficult it is to treat. Guan Qiuhong et al. believe that inappropriate tonification is also a common cause of cough after a cold. Over-supplementation or improper diet can internally injure the spleen and stomach, water dampness stops internally, and is stored in the lungs. Some people think that this disease is mostly caused by wind-heat invading the lungs, violent rage and liver damage, prolonged emotional damage, abnormal qi mechanism, relapse of exogenous pathogens, transformation of heat and blazing body fluid; caused by the throat. It is also believed that the disease is caused by stagnation of liver qi, dysfunction of the spleen, and weak stomach qi, so that body fluid cannot go up to the throat. There are also many doctors who discuss treatment from the perspective of pathological products, advocate treatment from phlegm and blood stasis, and believe that "phlegm" and "stasis" are the most common pathological factors in the pathogenesis of chronic pharyngitis, and phlegm and blood stasis coexist. Some studies have divided PIC into 5 types: the treatment of wind-evil love lung type is mainly to eliminate pathogens, the treatment of cold drink subduing the lung type is to warm the lungs and transform drink to dispel cold, and the treatment of phlegm-heat accumulation in the lung type is mainly to clear the lungs and resolve phlegm. Liver-fire invading the lungs clears the lungs, relieves coughs, softens the liver and relieves urgency, while the type of deficiency of the lung-spleen spleen mainly nourishes the lungs and spleen. "Traditional Chinese Medicine Clinical Diagnosis and Treatment Terminology and Syndrome Part" divides post-cold cough into three types: yin deficiency and internal heat type, qi deficiency and phlegm dampness type, and liver depression and qi stagnation type.
本发明的中药组合物为来源于临床的有效经验方,在长期临床实践中积累了大量的临床 病例,为一个4味中药组成的小复方,配伍精当、化裁有度,有利于组合物制剂的质量控制和工艺研究。其中: The traditional Chinese medicine composition of the present invention is an effective empirical prescription derived from clinical practice. A large number of clinical cases have been accumulated in long-term clinical practice. It is a small compound prescription composed of four traditional Chinese medicines. quality control and process research. in:
威灵仙:性辛、成,温。归膀胱经。具有祛风湿,通经络功效,用于风湿痹痛,肢体麻木,筋脉拘挛,屈伸不利。为此方中的君药,由于威灵仙的祛风湿作用,对于感冒后咳嗽中最常见的风邪犯肺型十分对症,起到疏风宣肺之作用。 Clematis: property pungent, Cheng, warm. Return bladder channel. Have dispelling rheumatism, dredge meridian effect, be used for rheumatism arthralgia, numbness of limbs, spasms of muscles and vessels, dysflexion and extension. For this reason, the monarch drug in this prescription, due to the rheumatism-dispelling effect of Clematis, is very symptomatic for the most common type of wind-evil attacking the lungs in post-cold cough, and plays the role of dispersing wind and promoting lungs.
石菖蒲:性辛、苦,温。归心、胃经。具有开窍豁痰,醒神益智,化湿开胃作用。用于神昏癫痫,健忘失眠,耳鸣耳聋,脘痞不饥,噤口下痢。为此方中的佐药,石菖蒲在治疗感冒后咳嗽中不论哪种类型均有化痰利咽之作用。 Herba Acorus: property is pungent, bitter, warm. GUIXIN, Stomach Meridian. Have one's ideas straightened out expel phlegm, refresh the mind and improve intelligence, eliminate dampness and whet the appetite. For stupor epilepsy, forgetful insomnia, tinnitus and deafness, gastral cavity ruffian is not hungry, and dysentery. As an adjuvant in this prescription, Shichangpu has the effect of reducing phlegm and relieving throat in the treatment of cough after a cold.
郁金:性辛、苦,寒。归肝、心、肺经。具有活血止痛,行气解郁,清心凉血,利胆退黄功效。用于胸胁刺痛,胸痹心痛。为此方中的臣药。郁金在对肝郁气滞型咳嗽的治疗中,能很好起到行气解郁之功效。 Radix Curcumae: acrid, bitter, cold in nature. Return liver, heart, lung meridian. It has the effects of promoting blood circulation and relieving pain, promoting qi circulation and relieving depression, clearing away heart-fire and cooling blood, promoting gallbladder and reducing jaundice. For thoracic hypochondrium tingling pain, obstruction of the chest and heartache. This is the ministerial medicine in the side. In the treatment of cough due to liver depression and qi stagnation, turmeric can play a very good role in promoting qi and relieving depression.
薄荷:性辛,凉。归肺、肝经。具有疏散风热,清利头目,利咽,透疹,疏肝行气功效。用于风热感冒,风温初起,头痛,目赤,喉痹,口疮,风疹,麻疹,胸胁胀闷,为此方中的使药。 Peppermint: pungent in nature, cool. Return lung, Liver Channel. It has the effects of dispersing wind-heat, clearing the head, relieving the throat, clearing the rash, soothing the liver and promoting qi. It is used for wind-heat and cold, the beginning of wind-temperature, headache, red eyes, sore throat, aphtha, rubella, measles, chest and hypochondrium, and it is the medicine in this prescription.
发明内容 Contents of the invention
本发明的目的是提供一种中药组合物; The object of the present invention is to provide a kind of Chinese medicine composition;
本发明的目的还在于提供该组合物的制备方法; The object of the present invention is also to provide a preparation method of the composition;
本发明的目的还在于提供该中药组合物的用途; The object of the present invention is also to provide the purposes of this traditional Chinese medicine composition;
本发明的目的还在于提供该中药组合物的质量控制方法。 The object of the present invention is also to provide a quality control method of the traditional Chinese medicine composition.
本发明的目的是通过以下方式实现的: The purpose of the present invention is achieved in the following manner:
一种治疗感冒后咳嗽的中药组合物,是由以下重量比的原料药组成:威灵仙6-20克、郁金6-20克、石菖蒲3-10克、薄荷3-10克。 The traditional Chinese medicine composition for treating post-cold cough is composed of raw materials in the following weight ratios: 6-20 grams of Clematis, 6-20 grams of Curcuma, 3-10 grams of Shichangpu, and 3-10 grams of Peppermint.
上述原料,威灵仙来源于毛茛科植物威灵仙Clematis chinensis Osbeck、棉团铁线莲Clematis hexapetala Pall.或东北铁线莲Clematis manshurica Rupr.的干燥根及根茎;郁金来源于姜科植物温郁金Curcuma wenyujin Y.H.Chen et C.Ling、姜黄Curcuma longa L.、广西莪术Curcuma kwangsiensis S.G.Lee et C.F.Liang或蓬莪术Curcuma phaeocaulis Val.的干燥块根。前两者分别习称“温郁金”和“黄丝郁金”,其余按性状不同习称“桂郁金”或“绿丝郁金”;石菖蒲来源于天南星科植物石菖蒲Acorus tatarinowii Schott的干燥根茎。薄荷来源于唇形科植物薄荷Metha haplocalyx Briq.的干燥地上部分。 The above raw materials, Clematis chinensis Osbeck, Clematis hexapetala Pall. or Clematis manshurica Rupr. dry roots and rhizomes of Clematis chinensis Osbeck of Ranunculaceae; Dry roots of Curcuma wenyujin Y.H.Chen et C.Ling, Curcuma longa L., Curcuma kwangsiensis S.G.Lee et C.F.Liang or Curcuma phaeocaulis Val. The first two are commonly called "warm turmeric" and "yellow silk turmeric", and the rest are commonly called "osmanthus turmeric" or "green turmeric" according to their different characters; Acorus tatarinowii Schott is derived from the dried rhizome. Mint is derived from the dry aerial part of the mint Metha haplocalyx Briq.
所述中药组合物优选由以下重量比的原料药组成:威灵仙10克、郁金10克、石菖蒲6 克、薄荷6克。 The traditional Chinese medicine composition is preferably composed of raw materials in the following weight ratio: 10 grams of Clematis, 10 grams of Curcuma, 6 grams of Shichangpu, and 6 grams of Peppermint.
所述中药组合物优选由以下重量比的原料药组成:威灵仙6克、郁金15克、石菖蒲6克、薄荷9克。 The traditional Chinese medicine composition is preferably composed of raw materials in the following weight ratios: 6 grams of Clematis, 15 grams of Curcuma, 6 grams of Shichangpu, and 9 grams of Peppermint.
所述中药组合物优选由以下重量比的原料药组成:威灵仙12克、郁金10克、石菖蒲6克、薄荷6克。 The traditional Chinese medicine composition is preferably composed of raw materials in the following weight ratio: 12 grams of Clematis, 10 grams of Curcuma, 6 grams of Shichangpu, and 6 grams of Peppermint.
所述中药组合物优选由以下重量比的原料药组成:威灵仙15克、郁金12克、石菖蒲9克、薄荷3克。 The traditional Chinese medicine composition is preferably composed of raw materials in the following weight ratios: 15 grams of Clematis clematis, 12 grams of curcuma, 9 grams of Shichangpu, and 3 grams of peppermint.
所述中药组合物优选由以下重量比的原料药组成:威灵仙20克、郁金15克、石菖蒲3克、薄荷9克。 The traditional Chinese medicine composition is preferably composed of raw materials in the following weight ratios: 20 grams of Clematis, 15 grams of Curcuma, 3 grams of Shichangpu, and 9 grams of Peppermint.
上述中药组合物的制备方法为:威灵仙、薄荷、石菖蒲及郁金药材,加入药材总量6-12倍水,以水蒸气蒸馏法提取挥发油5-9小时,收集挥发油,加入吐温-80增溶,备用;将水蒸气蒸馏提取液过滤,得提油母液和滤渣;滤渣加入6-10倍水煎煮1-3次,每次1-3小时,合并煎煮液与提油母液,将上清液浓缩后加75-95%乙醇使含醇量达65-85%,冷藏静置后取出,滤过,滤液减压回收乙醇至无醇味;加入增溶后的挥发油以及常规药用辅料,采用中药药剂学中常规的制剂方法,制成适宜剂型。 The preparation method of the above-mentioned Chinese medicine composition is as follows: Clematis clematis, mint, calamus and turmeric medicinal materials, adding 6-12 times the water of the total amount of medicinal materials, extracting volatile oil by steam distillation for 5-9 hours, collecting volatile oil, adding Tween Solubilize at -80, set aside; filter the steam distillation extract to obtain the oil mother liquor and filter residue; add 6-10 times the water to the filter residue and decoct 1-3 times, 1-3 hours each time, combine the decoction and oil extraction Mother liquor, after concentrating the supernatant, add 75-95% ethanol to make the alcohol content reach 65-85%, take it out after refrigerating and standing still, filter, and recover the ethanol from the filtrate under reduced pressure until it has no alcohol smell; add the solubilized volatile oil and Conventional pharmaceutical excipients are made into suitable dosage forms by conventional preparation methods in traditional Chinese medicine pharmacy.
上述制备方法优选为:威灵仙、薄荷、石菖蒲及郁金药材,加入药材总量12倍水,以水蒸气蒸馏法提取挥发油7小时,收集挥发油,母液过滤,加入吐温-80增溶,备用;水蒸气蒸馏提取液过滤,得提油母液和滤渣;滤渣加入10倍水煎煮3次,每次2小时,合并煎煮液与提油母液,将上清液浓缩后加95%乙醇使含醇量达65%,冷藏静置15h后取出,滤过,滤液减压回收乙醇至无醇味;加入增溶后的挥发油以及常规药用辅料,采用中药药剂学中常规的制剂方法,制成颗粒剂、口服片、口含片、分散片、硬胶囊剂、软胶囊剂、口服液、喷雾剂、粉末型喷剂。 The above preparation method is preferably: Clematis clematis, peppermint, calamus and turmeric medicinal materials, adding 12 times the total amount of medicinal materials, extracting volatile oil by steam distillation for 7 hours, collecting volatile oil, filtering the mother liquor, adding Tween-80 for solubilization , and set aside; the steam distillation extract was filtered to obtain the oil extraction mother liquor and the filter residue; the filter residue was added to 10 times of water and decocted for 3 times, each time for 2 hours, the decoction and the oil extraction mother liquor were combined, and the supernatant was concentrated and then added with 95% Ethanol makes the alcohol content reach 65%, take it out after refrigerating and standing for 15 hours, filter, and recover the ethanol from the filtrate under reduced pressure until it has no alcohol smell; add the solubilized volatile oil and conventional pharmaceutical excipients, and adopt the conventional preparation method in traditional Chinese medicine pharmacy , made into granules, oral tablets, buccal tablets, dispersible tablets, hard capsules, soft capsules, oral liquids, sprays, powder sprays.
本发明中药组合物优选的剂型为口服液,其制备方法为:威灵仙、薄荷、石菖蒲及郁金药材,加入药材总量12倍水,以水蒸气蒸馏法提取挥发油7小时,收集挥发油,加入吐温-80增溶,备用;将水蒸气蒸馏提取液过滤,得提油母液和滤渣;滤渣加入10倍水煎煮3次,每次2小时,合并煎煮液与提油母液,将上清液浓缩后加95%乙醇使含醇量达65%,冷藏静置15h后取出,滤过,滤液减压回收乙醇至无醇味;加入增溶后的挥发油以及单糖浆、甜菊糖和苯甲酸钠,定容,分装于口服液瓶中,即得。 The preferred dosage form of the Chinese medicine composition of the present invention is oral liquid, and its preparation method is: Clematis clematis, peppermint, Shichangpu and turmeric medicinal materials, adding 12 times of water of the total amount of medicinal materials, extracting volatile oil with steam distillation for 7 hours, collecting volatile oil , add Tween-80 to solubilize, and set aside; filter the steam distillation extract to obtain oil extraction mother liquor and filter residue; add 10 times water to decoct the filter residue 3 times, each time for 2 hours, combine the decoction and oil extraction mother liquor, After concentrating the supernatant, add 95% ethanol to make the alcohol content reach 65%, take it out after refrigerating and standing for 15 hours, filter, and recover the ethanol from the filtrate under reduced pressure until it has no alcohol taste; add the solubilized volatile oil, simple syrup and stevioside And sodium benzoate, constant volume, sub-packed in oral liquid bottles, to get.
本发明的中药组合物还可以采用如下方法制备:威灵仙、薄荷、石菖蒲及郁金药材,加入药材总量5-15倍的50-80%乙醇回流提取,提取次数1-4次,每次0.5-4小时,醇提液合并,过滤,滤液浓缩,加入常规药用辅料,采用中药药剂学中常规的制剂方法,制成适宜剂型。 The Chinese medicine composition of the present invention can also be prepared by the following method: Clematis clematis, peppermint, calamus and turmeric medicinal materials are added to reflux extraction with 50-80% ethanol 5-15 times the total amount of medicinal materials, and the extraction times are 1-4 times. Each time for 0.5-4 hours, the alcohol extracts are combined, filtered, the filtrate is concentrated, conventional pharmaceutical excipients are added, and a suitable dosage form is prepared by adopting a conventional preparation method in traditional Chinese medicine pharmacy.
上述制备方法优选为:威灵仙、薄荷、石菖蒲及郁金药材,加70%乙醇回流提取2次,每次3小时,醇提液合并,过滤,浓缩,加入常规药用辅料,采用中药药剂学中常规的制剂方法,制成颗粒剂、口服片、口含片、分散片、硬胶囊剂、软胶囊剂、口服液、喷雾剂、粉末型喷剂。 The above preparation method is preferably: Clematis clematis, mint, calamus and turmeric medicinal materials, add 70% ethanol to reflux extraction twice, each time for 3 hours, combine the alcohol extracts, filter, concentrate, add conventional pharmaceutical excipients, use traditional Chinese medicine The conventional preparation methods in pharmacy are made into granules, oral tablets, buccal tablets, dispersible tablets, hard capsules, soft capsules, oral liquids, sprays, and powder sprays.
本发明中药组合物优选的剂型为口服液,其制备方法为:威灵仙、薄荷、石菖蒲及郁金药材,加70%乙醇回流提取2次,每次3小时,醇提液合并,过滤,浓缩,加入单糖浆、甜菊糖和苯甲酸钠,定容,分装于口服液瓶中,即得。 The preferred dosage form of the traditional Chinese medicine composition of the present invention is oral liquid, and its preparation method is: Clematis clematis, peppermint, calamus and turmeric medicinal materials, add 70% ethanol and reflux extraction twice, each time for 3 hours, the ethanol extracts are combined, filtered , concentrate, add simple syrup, stevioside and sodium benzoate, dilute to volume, pack in oral liquid bottles, and get ready.
本发明的中药组合物还可以采用如下方法制备:威灵仙、薄荷、石菖蒲及郁金药材,加入药材总量6-12倍水,以水蒸气蒸馏法提取挥发油5-9小时,收集挥发油,β-环糊精包合,得到包合物备用:将水蒸气蒸馏提取液过滤,得提油母液和滤渣;滤渣加入6-10倍水煎煮1-3次,每次1-3小时,合并煎煮液与提油母液,将上清液浓缩后加75-95%乙醇使含醇量达65-85%,冷藏静置后取出,滤过,滤液减压回收乙醇至无醇味,然后继续浓缩至稠膏,干燥,所得干燥物与挥发油包合物混合均匀,加入常规药用辅料,采用中药药剂学中常规的制剂方法,制成适宜剂型。 The Chinese medicine composition of the present invention can also be prepared by the following method: Clematis clematis, mint, calamus and turmeric medicinal materials, add 6-12 times of water of the total amount of medicinal materials, extract volatile oil for 5-9 hours with steam distillation, collect volatile oil , β-cyclodextrin inclusion complex, to obtain inclusion compound for later use: filter the steam distillation extract to obtain oil mother liquor and filter residue; add 6-10 times of water to the filter residue and decoct 1-3 times, 1-3 hours each time , combine the decoction liquid and oil extraction mother liquor, concentrate the supernatant, add 75-95% ethanol to make the alcohol content reach 65-85%, take it out after refrigerating and standing still, filter, and recover the ethanol from the filtrate under reduced pressure until it has no alcohol smell , and then continue to concentrate to a thick paste, dry, and mix the obtained dried product with the volatile oil clathrate evenly, add conventional pharmaceutical excipients, and adopt the conventional preparation method in traditional Chinese medicine pharmacy to make a suitable dosage form.
上述制备方法优选为:威灵仙、薄荷、石菖蒲及郁金药材,加入药材总量12倍水,以水蒸气蒸馏法提取挥发油7小时,收集挥发油,β-环糊精包合,冷藏过夜,滤过,低温烘干,即得到β-环糊精包合物备用;将水蒸气蒸馏提取液过滤,得提油母液和滤渣;滤渣加入10倍水煎煮3次,每次2小时,合并煎煮液与提油母液,将上清液浓缩后加95%乙醇使含醇量达65%,冷藏静置15h后取出,滤过,滤液减压回收乙醇至无醇味,然后继续浓缩至稠膏,干燥,所得干燥物与挥发油包合物混合均匀,加入常规药用辅料,采用中药药剂学中常规的制剂方法,制成颗粒剂、口服片、口含片、分散片、硬胶囊剂、软胶囊剂、口服液、喷雾剂、粉末型喷剂。 The above preparation method is preferably: Clematis clematis, peppermint, calamus and turmeric medicinal materials, adding 12 times the total amount of medicinal materials, extracting volatile oil by steam distillation for 7 hours, collecting volatile oil, β-cyclodextrin inclusion, and refrigerating overnight , filter, and dry at low temperature to obtain β-cyclodextrin inclusion compound for later use; filter the steam distillation extract to obtain oil mother liquor and filter residue; add 10 times water to the filter residue and decoct 3 times, 2 hours each time, Combine the decoction liquid and the oil extraction mother liquid, concentrate the supernatant, add 95% ethanol to make the alcohol content reach 65%, refrigerate and stand for 15 hours, take it out, filter, and recover the ethanol from the filtrate under reduced pressure until there is no alcohol smell, and then continue to concentrate To a thick paste, dry, and mix the obtained dried product with the volatile oil inclusion compound evenly, add conventional pharmaceutical excipients, and adopt conventional preparation methods in traditional Chinese medicine pharmacy to make granules, oral tablets, buccal tablets, dispersible tablets, and hard capsules Agents, soft capsules, oral liquids, sprays, powder sprays.
本发明中药组合物优选的剂型还有口含片,其制备方法为:威灵仙、薄荷、石菖蒲及郁金药材,加入药材总量12倍水,以水蒸气蒸馏法提取挥发油7小时,收集挥发油,β-环糊精包合,冷藏过夜,滤过,低温烘干,即得到β-环糊精包合物备用;将水蒸气蒸馏提取液过滤,得提油母液和滤渣;滤渣加入10倍水煎煮3次,每次2小时,合并煎煮液与提油母液,将上清液浓缩后加95%乙醇使含醇量达65%,冷藏静置15h后取出,滤过,滤液减压回收乙醇至无醇味,然后继续浓缩至稠膏,干燥,所得干燥物与挥发油包合物混合均匀,加入糊精、蔗糖粉、甜菊糖、香精,湿法制粒,干燥后整粒,加入0.5%硬脂酸镁,混合均匀,压制成口含片即得。 The preferred dosage form of the Chinese medicine composition of the present invention also has buccal tablets, and its preparation method is: Clematis clematis, mint, calamus and turmeric medicinal materials, add 12 times of water of the total amount of medicinal materials, extract volatile oil with steam distillation for 7 hours, Collect volatile oil, β-cyclodextrin inclusion complex, refrigerate overnight, filter, and dry at low temperature to obtain β-cyclodextrin inclusion complex for later use; filter the steam distillation extract to obtain oil mother liquor and filter residue; add the filter residue Decoct with 10 times water for 3 times, 2 hours each time, combine the decoction liquid and the mother liquid for extracting oil, concentrate the supernatant, add 95% ethanol to make the alcohol content reach 65%, refrigerate and stand for 15 hours, take it out, filter, The filtrate is decompressed to recover ethanol until it has no alcohol smell, then continue to concentrate to a thick paste, dry, and mix the obtained dried product with volatile oil clathrate evenly, add dextrin, sucrose powder, stevioside, essence, wet granulation, and granulate after drying , add 0.5% magnesium stearate, mix evenly, and compress into buccal tablets.
本发明的中药组合物质量控制方法包括如下鉴别方法和/或含量测定的一种或几种: The quality control method of the traditional Chinese medicine composition of the present invention includes one or more of the following identification methods and/or content determination:
鉴别: Identification:
取本发明的中药组合物制剂内容物2-10mL置于圆底烧饼中,加入2mol/L的HCl30-100mL,水浴回流1-3小时,放凉后置于分液漏斗中,加入乙酸乙酯萃取1-3次,每次15-30mL,合并萃取液加压蒸干,甲醇定容至5-10mL,作为供试品溶液。另取齐墩果酸和常春藤皂常苷元对照品加甲醇制成每1mL含1mg,作为对照品溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各1-5μl,分别点于同一硅胶G薄层板上,以石油醚-乙酸乙酯-甲酸(5-20∶1-10∶0.1-1)为展开剂,薄层板置展开缸中预饱和30分钟,展开,取出,晾干,喷以10%硫酸乙醇溶液,在105℃加热至斑点显色清晰。供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的斑点。 Take 2-10mL of the content of the traditional Chinese medicine composition preparation of the present invention and place it in a round-bottomed sesame cake, add 2mol/L HCl30-100mL, reflux in a water bath for 1-3 hours, put it in a separatory funnel after cooling, add ethyl acetate Extract 1-3 times, 15-30mL each time, combine the extracts and evaporate to dryness under pressure, dilute to 5-10mL with methanol, and use it as the test solution. Take another oleanolic acid and hedera saponin reference substance plus methanol to make each 1mL containing 1mg, as the reference solution. Test according to thin-layer chromatography ("Chinese Pharmacopoeia" 2010 edition appendix VI B), draw each 1-5 μ l of the above-mentioned two kinds of solutions, point respectively on the same silica gel G thin-layer plate, add petroleum ether-ethyl acetate-formic acid (5 -20∶1-10∶0.1-1) as the developing agent, place the thin-layer plate in the developing cylinder and pre-saturate for 30 minutes, develop, take out, dry in the air, spray with 10% sulfuric acid ethanol solution, and heat at 105°C until the spots develop color clear. In the chromatogram of the test product, there are spots of the same color at the position corresponding to the chromatogram of the reference product.
取本发明的中药组合物制剂内容物2-10mL置于分液漏斗中,加入石油醚萃取1-3次,每次5-15mL,合并乙醚,减压蒸干后加入2-10mL甲醇定容,作为供试品溶液。另取薄荷对照药材,粉碎过40目筛,取0.5g加5-15mL石油醚超声30min,过滤后,滤液蒸干并定容至1mL,,作为对照药材溶液。另取薄荷醇对照品加甲醇制成每1ml含2mg,作为对照品溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各1-5μl,分别点于同一硅胶G薄层板上,以甲苯-乙酸乙酯(5-20∶1-5)为展开剂,预饱和30min后,展开,取出,晾干,喷以2%香草醛硫酸-乙醇(1∶4)显色剂,105℃加热至斑点显色清晰。供试品色谱中,在与对照品、对照药材色谱相应的位置上,显相同颜色的斑点。 Take 2-10mL of the content of the traditional Chinese medicine composition preparation of the present invention and place it in a separatory funnel, add petroleum ether to extract 1-3 times, 5-15mL each time, combine ether, evaporate to dryness under reduced pressure, add 2-10mL methanol to constant volume , as the test solution. Another mint reference medicinal material was taken, crushed through a 40-mesh sieve, 0.5 g was added to 5-15 mL of petroleum ether and ultrasonicated for 30 minutes, filtered, the filtrate was evaporated to dryness and the volume was adjusted to 1 mL, as the reference medicinal material solution. Another menthol reference substance plus methanol made per 1ml containing 2mg, as the reference substance solution. Test according to thin-layer chromatography (appendix VI B of "Chinese Pharmacopoeia" 2010 edition), draw 1-5 μ l of each of the above two solutions, and place them on the same silica gel G thin-layer plate respectively, and use toluene-ethyl acetate (5-20: 1-5) is the developing agent. After pre-saturation for 30 minutes, develop, take out, dry in the air, spray with 2% vanillin sulfuric acid-ethanol (1:4) color developer, and heat at 105°C until the spots are clearly colored. In the chromatogram of the test product, there are spots of the same color at the positions corresponding to the chromatogram of the reference substance and the reference medicinal material.
取本发明的中药组合物制剂内容物2-10mL,加入无水乙醇25-50mL超声15-30min,滤过,减压回收溶剂,残渣用1mL乙醇溶解,作为供试品溶液。另取郁金对照药材,粉碎过40目筛,取0.5-2g,加5-50mL乙醇超声30min,过滤,定容至1mL作为对照药材溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各1-5μl,分别点于同一硅胶G薄层板上,以石油醚(60-90℃)-乙酸乙酯(10-30∶5-10)为展开剂,预饱和30min后,展开,取出晾干,喷以10%浓硫酸乙醇显色剂,105℃加热至斑点显色清晰。供试品色谱中,在与对照药材色谱相应的位置上,显相同颜色的斑点。 Take 2-10mL of the content of the traditional Chinese medicine composition preparation of the present invention, add 25-50mL of absolute ethanol and sonicate for 15-30min, filter, recover the solvent under reduced pressure, and dissolve the residue with 1mL of ethanol as the test solution. Take another curcuma reference medicinal material, crush it through a 40-mesh sieve, take 0.5-2 g, add 5-50 mL of ethanol and sonicate for 30 minutes, filter, and dilute to 1 mL as the reference medicinal material solution. According to the test of thin-layer chromatography (Appendix VI B of "Chinese Pharmacopoeia" 2010 edition), draw 1-5 μl of each of the above two solutions, respectively spot on the same silica gel G thin-layer plate, and use petroleum ether (60-90 ° C)-acetic acid Ethyl ester (10-30:5-10) was used as the developing agent. After pre-saturation for 30 minutes, develop, take out and dry in the air, spray with 10% concentrated sulfuric acid ethanol color developer, and heat at 105°C until the spots are clearly colored. In the chromatogram of the test product, there are spots of the same color at the position corresponding to the chromatogram of the control medicinal material.
取本发明的中药组合物制剂内容物2-10mL置于分液漏斗中,加入石油醚萃取1-3次,每次5-15mL,合并乙醚,减压蒸干后加入2-10mL甲醇定容,作为供试品溶液。另取石菖蒲对照药材,粉碎过40目筛,取0.5-2g,加10-40mL乙醚超声30min,过滤后,滤液蒸干并定容至1mL,作为供试品溶液。另取α-细辛醚对照品加甲醇制备成每mL含2mg,作为对照品溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各1-5μl,分别点于同一硅胶G薄层板上,以石油醚(60-90℃)-乙酸乙酯(5-20∶2-20)为展开剂,预饱和 30min后,展开,取出,晾干,置紫外光灯(365nm)下检视。供试品色谱中,在与对照品溶液色谱相应的位置上,显相同颜色的斑点。 Take 2-10mL of the content of the traditional Chinese medicine composition preparation of the present invention and place it in a separatory funnel, add petroleum ether to extract 1-3 times, 5-15mL each time, combine ether, evaporate to dryness under reduced pressure, add 2-10mL methanol to constant volume , as the test solution. Another reference medicinal material, Shichangpu, was crushed through a 40-mesh sieve, and 0.5-2 g was taken, and 10-40 mL of ether was added for ultrasonication for 30 minutes. After filtration, the filtrate was evaporated to dryness and the volume was adjusted to 1 mL, as the test solution. Another α-asarone reference substance plus methanol prepared to contain 2mg per mL, as the reference substance solution. According to the test of thin-layer chromatography (Appendix VI B of "Chinese Pharmacopoeia" 2010 edition), draw 1-5 μl of each of the above two solutions, respectively spot on the same silica gel G thin-layer plate, and use petroleum ether (60-90 ° C)-acetic acid Ethyl ester (5-20:2-20) was used as the developer, pre-saturated for 30 minutes, developed, taken out, dried in the air, and inspected under an ultraviolet lamp (365nm). In the chromatogram of the test product, there are spots of the same color at the position corresponding to the chromatogram of the reference substance solution.
含量测定: Content determination:
色谱条件:十八烷基硅烷键合硅胶为填充剂;流动相为乙腈(A)-0.1-0.5%磷酸(B),梯度洗脱(0~15min:70%A,15~20min:70%→90%A,20~30min:90%A,30~35:90%→70%);柱温30℃;流速1.0ml·min-1,检测波长205nm。外标法峰面积定量。 Chromatographic conditions: octadecylsilane bonded silica gel as filler; mobile phase is acetonitrile (A)-0.1-0.5% phosphoric acid (B), gradient elution (0-15min: 70%A, 15-20min: 70% →90%A, 20-30min: 90%A, 30-35: 90%→70%); column temperature 30°C; flow rate 1.0ml·min-1, detection wavelength 205nm. Quantification of peak area by external standard method.
对照品溶液制备:称取在60℃减压干燥3-5小时的常春藤皂苷元、齐墩果酸对照品,加甲醇制成每1ml含20ug的浓度即得。 Preparation of reference substance solution: Weigh the reference substances of hedera saponin and oleanolic acid dried under reduced pressure at 60°C for 3-5 hours, add methanol to obtain a concentration of 20ug per 1ml.
供试品溶液制备:量取中药组合物制剂内容物1-5ml,加2mol/L盐酸溶液10-50ml,加热回流1-3小时,立即冷却,移入分液漏斗中,加乙酸乙酯振摇提取1-3次,每次10-30ml,合并乙酸乙酯液,蒸干,加甲醇溶解,转移至5ml量瓶中,定容即得。 Preparation of the test solution: Measure 1-5ml of the content of the traditional Chinese medicine composition preparation, add 10-50ml of 2mol/L hydrochloric acid solution, heat and reflux for 1-3 hours, cool immediately, transfer to a separatory funnel, add ethyl acetate to shake Extract 1-3 times, 10-30ml each time, combine the ethyl acetate solution, evaporate to dryness, add methanol to dissolve, transfer to a 5ml measuring bottle, and set to volume.
测定法:分别吸取对照品溶液与供试品溶液各10ul,注入液相色谱仪,测定,即得。 Determination method: draw respectively 10ul of the reference substance solution and the test solution, inject it into the liquid chromatograph, measure it, and obtain it.
本发明中药组合物的口服液中每毫升克含威灵仙以常春藤皂苷元计不得少于0.60-1.00mg,以齐墩果酸计不得少于0.10-0.40mg。 The oral liquid of the traditional Chinese medicine composition of the present invention contains not less than 0.60-1.00 mg of Clematis per milligram in terms of hedera saponin, and not less than 0.10-0.40 mg in terms of oleanolic acid.
本发明的中药组合物质量控制方法优选为如下鉴别方法和/或含量测定的一种或几种: The quality control method of the Chinese medicine composition of the present invention is preferably one or more of the following identification methods and/or content determination:
鉴别: Identification:
取本发明的中药组合物制剂2mL置于圆底烧饼中,加入2mol/L的HCl 30mL,水浴回流2小时,放凉后置于分液漏斗中,加入乙酸乙酯萃取3次,每次15mL,合并萃取液加压蒸干,甲醇定容至10mL,作为供试品溶液。另取齐墩果酸和常春藤皂常苷元对照品加甲醇制成每1mL含1mg,作为对照品溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各5μl,分别点于同一硅胶G薄层板上,以石油醚-乙酸乙酯-甲酸(10∶3∶0.1)为展开剂,薄层板置展开缸中预饱和30分钟,展开,取出,晾干,喷以10%硫酸乙醇溶液,在105℃加热至斑点显色清晰。供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的斑点。 Take 2 mL of the Chinese medicine composition preparation of the present invention and place it in a round-bottomed sesame seed cake, add 30 mL of 2mol/L HCl, reflux in a water bath for 2 hours, put it in a separating funnel after cooling, add ethyl acetate to extract 3 times, 15 mL each time , The combined extracts were evaporated to dryness under pressure, and the volume was adjusted to 10 mL with methanol as the test solution. Take another oleanolic acid and hedera saponin reference substance plus methanol to make each 1mL containing 1mg, as the reference solution. According to the thin-layer chromatography (Appendix VI B of "Chinese Pharmacopoeia" 2010 edition), draw 5 μl of each of the above two solutions, respectively spot on the same silica gel G thin-layer plate, and use petroleum ether-ethyl acetate-formic acid (10:3 : 0.1) as the developing agent, the thin-layer plate was placed in a developing cylinder and pre-saturated for 30 minutes, developed, taken out, dried in the air, sprayed with 10% sulfuric acid ethanol solution, and heated at 105°C until the spots were clearly colored. In the chromatogram of the test product, there are spots of the same color at the position corresponding to the chromatogram of the reference product.
取本发明的中药组合物制剂2mL置于分液漏斗中,加入石油醚萃取3次,每次5mL,合并乙醚,减压蒸干后加入2mL甲醇定容,作为供试品溶液。另取薄荷对照药材,粉碎过40目筛,取0.5g加10mL石油醚超声30min,过滤后,滤液蒸干并定容至1mL,作为对照药材溶液。另取薄荷醇对照品加甲醇制成每1ml含2mg,作为对照品溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各2μl,分别点于同一硅胶G薄层板上,以甲苯-乙酸乙酯(8∶18)为展开剂,预饱和30min后,展开,取出,晾干,喷以2%香草醛硫 酸-乙醇(1∶4)显色剂,105℃加热至斑点显色清晰。供试品色谱中,在与对照品、对照药材色谱相应的位置上,显相同颜色的斑点。 Take 2 mL of the Chinese medicine composition preparation of the present invention and place it in a separatory funnel, add petroleum ether to extract 3 times, 5 mL each time, combine ether, evaporate to dryness under reduced pressure, add 2 mL of methanol to constant volume, as the test solution. Take mint as a control medicinal material, crush it through a 40-mesh sieve, take 0.5 g and add 10 mL of petroleum ether to sonicate for 30 minutes, filter, evaporate the filtrate to dryness and dilute to 1 mL, and use it as the reference medicinal material solution. Another menthol reference substance plus methanol made per 1ml containing 2mg, as the reference substance solution. According to the thin-layer chromatography (Appendix VI B of "Chinese Pharmacopoeia" 2010 edition), draw 2 μl of each of the above two solutions, respectively spot on the same silica gel G thin-layer plate, and develop with toluene-ethyl acetate (8:18) After pre-saturation for 30 minutes, develop, take out, dry in the air, spray with 2% vanillin sulfuric acid-ethanol (1:4) color developer, heat at 105°C until the spots are clear in color. In the chromatogram of the test product, there are spots of the same color at the positions corresponding to the chromatogram of the reference substance and the reference medicinal material.
取本发明的中药组合物制剂2mL,加入无水乙醇25mL超声15min,滤过,减压回收溶剂,残渣用1mL乙醇溶解,作为供试品溶液。另取郁金对照药材,粉碎过40目筛,取2g,加25mL乙醇超声30min,过滤,定容至1mL作为对照药材溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各1-5μl,分别点于同一硅胶G薄层板上,以石油醚(60-90℃)-甲酸乙酯(15∶5)为展开剂,预饱和30min后,展开,取出晾干,喷以10%浓硫酸乙醇显色剂,105℃加热至斑点显色清晰。供试品色谱中,在与对照药材色谱相应的位置上,显相同颜色的斑点。 Get 2mL of the Chinese medicine composition preparation of the present invention, add 25mL of absolute ethanol and sonicate for 15min, filter, recover the solvent under reduced pressure, and dissolve the residue with 1mL of ethanol as the test solution. Take another curcuma reference medicinal material, crush it through a 40-mesh sieve, take 2 g, add 25 mL of ethanol to ultrasonic for 30 minutes, filter, and dilute to 1 mL as the reference medicinal material solution. According to the thin-layer chromatography (Appendix VI B of "Chinese Pharmacopoeia" 2010 edition), draw 1-5 μl of each of the above two solutions, respectively spot on the same silica gel G thin-layer plate, and use petroleum ether (60-90 ° C)-formic acid Ethyl ester (15:5) was used as the developing agent. After pre-saturation for 30 minutes, develop, take out and dry in the air, spray with 10% concentrated sulfuric acid ethanol color developer, and heat at 105°C until the spots are clearly colored. In the chromatogram of the test product, there are spots of the same color at the position corresponding to the chromatogram of the control medicinal material.
取本发明的中药组合物制剂5mL置于分液漏斗中,加入石油醚萃取3次,每次5mL,合并乙醚,减压蒸干后加入5mL甲醇定容,作为供试品溶液。另取石菖蒲对照药材,粉碎过40目筛,取1g,加10mL乙醚超声30min,过滤后,滤液蒸干并定容至1mL,作为供试品溶液。另取α-细辛醚对照品加甲醇制备成每mL含2mg,作为对照品溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各1-5μl,分别点于同一硅胶G薄层板上,以石油醚(60-90℃)-乙酸乙酯(6∶4)为展开剂,预饱和30min后,展开,取出,晾干,置紫外光灯(365nm)下检视。供试品色谱中,在与对照品溶液色谱相应的位置上,显相同颜色的斑点。 Get 5 mL of the Chinese medicine composition preparation of the present invention and place it in a separatory funnel, add petroleum ether to extract 3 times, 5 mL each time, combine ether, evaporate to dryness under reduced pressure, add 5 mL methanol to constant volume, as the test solution. Another reference medicinal material, Shichangpu, was crushed through a 40-mesh sieve, and 1 g was taken, and 10 mL of ether was added for ultrasonication for 30 minutes. After filtration, the filtrate was evaporated to dryness and the volume was adjusted to 1 mL, as the test solution. Another α-asarone reference substance plus methanol prepared to contain 2mg per mL, as the reference substance solution. According to the test of thin-layer chromatography (Appendix VI B of "Chinese Pharmacopoeia" 2010 edition), draw 1-5 μl of each of the above two solutions, respectively spot on the same silica gel G thin-layer plate, and use petroleum ether (60-90 ° C)-acetic acid Ethyl ester (6:4) was used as the developer, pre-saturated for 30min, developed, taken out, dried in the air, and inspected under ultraviolet light (365nm). In the chromatogram of the test product, there are spots of the same color at the position corresponding to the chromatogram of the reference substance solution.
含量测定: Content determination:
色谱条件:十八烷基硅烷键合硅胶为填充剂;流动相为乙腈(A)-0.1%磷酸(B),梯度洗脱(0~15min:70%A,15~20min:70%→90%A,20~30min:90%A,30~35:90%→70%);柱温30℃;流速1.0ml·min-1,检测波长205nm。外标法峰面积定量。 Chromatographic conditions: octadecylsilane bonded silica gel as filler; mobile phase is acetonitrile (A)-0.1% phosphoric acid (B), gradient elution (0~15min: 70%A, 15~20min: 70%→90 %A, 20-30min: 90%A, 30-35: 90%→70%); column temperature 30°C; flow rate 1.0ml·min -1 , detection wavelength 205nm. Quantification of peak area by external standard method.
对照品溶液制备:称取在60℃减压干燥4小时的常春藤皂苷元、齐墩果酸对照品,加甲醇制成每1ml含20ug的浓度即得。 Preparation of reference substance solution: Weigh the reference substance of hedera saponin and oleanolic acid dried under reduced pressure at 60°C for 4 hours, add methanol to make the concentration of 20ug per 1ml.
供试品溶液制备:量取中药组合物制剂内容物1ml,加2mol/L盐酸溶液30ml,加热回流3小时,立即冷却,移入分液漏斗中,加乙酸乙酯振摇提取3次,每次15ml,合并乙酸乙酯液,蒸干,加甲醇溶解,转移至5ml量瓶中,定容即得。 Preparation of the test solution: Measure 1ml of the content of the traditional Chinese medicine composition preparation, add 30ml of 2mol/L hydrochloric acid solution, heat and reflux for 3 hours, cool immediately, transfer to a separatory funnel, add ethyl acetate to shake and extract 3 times, each time 15ml, combined ethyl acetate solution, evaporated to dryness, dissolved in methanol, transferred to a 5ml measuring bottle, and made to volume.
测定法:分别吸取对照品溶液与供试品溶液各10ul,注入液相色谱仪,测定,即得。 Determination method: draw respectively 10ul of the reference substance solution and the test solution, inject it into the liquid chromatograph, measure it, and obtain it.
本发明中药组合物口服液中每毫升克含威灵仙以常春藤皂苷元计不得少于0.70mg,以齐墩果酸计不得少于0.25mg。 The oral liquid of the traditional Chinese medicine composition of the present invention contains not less than 0.70 mg of Clematis per milligram in terms of hedera saponin, and not less than 0.25 mg in terms of oleanolic acid.
上述权利要求的含量测定方法,其特征在于其中甲醇可以用70%乙醇或乙酸乙酯替代。 The assay method of the above claims, characterized in that methanol can be replaced by 70% ethanol or ethyl acetate.
上述权利要求的含量测定方法,其特征在于其中超声处理方法可以用回流提取方法替代。 The content determination method of the above claims, characterized in that the ultrasonic treatment method can be replaced by the reflux extraction method.
上述权利要求的含量测定方法,其特征在于其中超声处理方法可以用回流提取方法替代。 The content determination method of the above claims, characterized in that the ultrasonic treatment method can be replaced by the reflux extraction method.
上述权利要求的含量测定方法,其特征在于其中流动相乙腈-0.1%磷酸可以用乙腈-水替代。 The assay method of the above claims is characterized in that the mobile phase acetonitrile-0.1% phosphoric acid can be replaced by acetonitrile-water.
所述中药组合物在制备治疗感染性咳嗽药物中的应用。 Application of the traditional Chinese medicine composition in preparing medicine for treating infectious cough.
所述中药组合物在制备各类慢性咳嗽药物中的应用。 Application of the traditional Chinese medicine composition in preparing various chronic cough medicines.
下面的药学实验例用于进一步说明但不限于本发明。 The following pharmaceutical experiment examples are used to further illustrate but not limit the present invention.
实验例1:提油前是否需要浸泡考察 Experimental Example 1: Is it necessary to soak before oil extraction?
按处方称取药材170g共2份,加入10倍水,以水蒸气蒸馏法提取挥发油,一份浸泡,另一份不浸泡。10h后收集的挥发油量见下表,从下表1中可以看出药材浸泡收集挥发油总量为0.56ml,而不浸泡收集挥发油总量为0.48ml。因此,药材提油前需浸泡。 According to the prescription, 170g of the medicinal material was weighed in 2 parts, 10 times of water was added, and the volatile oil was extracted by steam distillation. One part was soaked, and the other part was not soaked. The amount of volatile oil collected after 10 hours is shown in the table below. From Table 1 below, it can be seen that the total amount of volatile oil collected by soaking medicinal materials is 0.56ml, and the total amount of volatile oil collected without soaking is 0.48ml. Therefore, medicinal materials need to be soaked before extracting oil.
表1 浸泡与否对挥发油量的影响 Table 1 Effect of soaking or not on the amount of volatile oil
实验例2:加水倍数考察 Experimental Example 2: Investigation of Water Adding Multiples
按处方称取药材170g共4份,分别加入8、10、12、14倍水,以水蒸气蒸馏提取挥发油,观察10h内累计提取挥发油量。表2为不同加水倍数时挥发油提取量。 According to the prescription, 170g of medicinal materials were weighed in 4 parts, and 8, 10, 12, 14 times of water were added respectively, and the volatile oil was extracted by steam distillation, and the cumulative amount of volatile oil extracted within 10 hours was observed. Table 2 shows the amount of volatile oil extracted at different times of adding water.
表2 加水倍数对挥发油量的影响 Table 2 Effect of water addition ratio on the amount of volatile oil
从表中挥发油提取的总量上看,加水12倍不浸泡所提挥发油量为0.51ml,优于其余加水倍数所提油量,而提取7小时后,挥发油量均为0.51ml左右,基本不增加,因此提取挥发油的最优工艺确定为加药材量12倍水,不浸泡,提油时间7小时。 From the total amount of volatile oil extracted in the table, the amount of volatile oil extracted by adding 12 times of water without soaking is 0.51ml, which is better than the amount of oil extracted by adding water multiples. After 7 hours of extraction, the amount of volatile oil is about 0.51ml, which is basically the same. Therefore, the optimal process for extracting volatile oil is determined as adding 12 times the amount of medicinal materials in water, without soaking, and the oil extraction time is 7 hours.
实验例3:提取工艺优化研究 Experimental Example 3: Extraction Process Optimization Research
确定处方药材提取挥发油后,药渣再进行水煎煮。水煎工艺参数优化采用正交设计法,以常春藤皂苷元、齐墩果酸的转移率及出膏率为指标,选择水提时间、水提次数、加水倍数 进行水提工艺考察。结果见表3、表4。 After the volatile oil is extracted from the prescribed medicinal materials, the dregs are decocted in water. Orthogonal design method was used to optimize the decoction process parameters. The transfer rate and ointment rate of hedera saponin and oleanolic acid were used as indicators, and the water extraction process was investigated by selecting the water extraction time, the number of water extraction times, and the multiple of water addition. The results are shown in Table 3 and Table 4.
表3 水提工艺的因素水平 Table 3 Factor levels of water extraction process
Table2-6 Factors and levels of water extraction of compound radix clematidis sprays Table2-6 Factors and levels of water extraction of compound radix clematidis sprays
表4 正交设计实验结果表 Table 4 Orthogonal design experiment results table
通过正交实验数据结果分析,发现水提取实验中影响威灵仙中常春藤皂苷元转移率的因素主次顺序为:次数>加水量>时间,即提取次数对威灵仙中常春藤皂苷元转移率的影响最显著,加水量次之,提取时间影响最小。考察三个因素在3个水平上的变化,时间因素的3水平、次数因素3水平及加水量的3水平的均值最大,为最优条件,故确定最佳工艺条件为加水煎煮3次,每次2小时,加水10倍量。 Through the analysis of the data results of the orthogonal experiment, it is found that the factors affecting the transfer rate of helexin in Clematis clematis in the water extraction experiment are in the order of primary and secondary: times > water amount > time, that is, the effect of extraction times on the transfer rate of helexin in Clematis clematis The most significant impact, followed by the amount of water added, the least impact of extraction time. Investigate the changes of the three factors on the three levels, the average value of the three levels of the time factor, the number of times factor and the amount of water added is the largest, which is the optimal condition, so the best process condition is determined as adding water and decocting three times, Every 2 hours, add 10 times the amount of water.
实验例4:醇沉工艺研究 Experimental Example 4: Research on Alcohol Precipitation Process
采用正交设计法,以常春藤皂苷元为指标,选择浓缩液浓度、醇沉积分数、静置时间进行醇沉工艺考察,因素水平见表5、表6。 Orthogonal design method was adopted, and hedera saponin was used as an index, and the concentrated solution concentration, alcohol deposition fraction, and standing time were selected to investigate the alcohol precipitation process. The factor levels are shown in Table 5 and Table 6.
表5 醇沉实验研究的因素水平 Table 5 Factor levels of alcohol precipitation experiments
表6 正交设计实验结果表 Table 6 Orthogonal design experiment results table
通过正交实验数据结果分析,发现醇沉实验中影响威灵仙中常春藤皂苷元转移率的因素主次顺序为:浓缩液浓度>静置时间>醇沉体积分数,即浓缩液浓度对威灵仙中常春藤皂苷元转移率的影响最显著,静置时间次之,醇沉体积分数影响最小。考察三个因素在3个水平上的变化,浓缩液浓度因素的2水平、醇沉体积分数因素1水平及静置时间的1水平的均值最大,为最优条件,故确定最佳工艺条件为浓缩液浓度(g/ml)为1.0,醇浓度为60%,静置时间为12小时。 Through the analysis of the data results of the orthogonal experiment, it is found that in the alcohol precipitation experiment, the factors affecting the transfer rate of helexin in Clematis clematis are in the order of primary and secondary: concentrated solution concentration > standing time > alcohol precipitation volume fraction, that is, the concentration of the concentrated solution has a significant effect on the transfer rate of Clematis clematis The transfer rate of helexin in Xianzhong had the most significant effect, followed by the standing time, and the alcohol precipitation volume fraction had the least effect. Investigate the changes of the three factors on the 3 levels, the average value of the 2 levels of the concentrated solution concentration factor, the 1 level of the alcohol precipitation volume fraction factor and the 1 level of the standing time is the largest, which is the optimal condition, so the optimum process conditions are determined as The concentrated solution concentration (g/ml) was 1.0, the alcohol concentration was 60%, and the standing time was 12 hours.
实验例5:矫味剂及用量的选择 Experimental example 5: the choice of flavoring agent and dosage
由于本中药组合物药液味道苦涩难以下咽,且咽服后舌头有明显厚重感,故需考虑加入适量的矫味剂,以改善制剂口感,提高患者用药顺应度。在矫味剂的选择上,加蔗糖及蜂蜜、红糖、阿斯巴甜等矫味后口感稍差,最终选择甜菊糖,并经多人品尝,对其用量进行筛选。最终选择加入0.33%甜菊糖为较适宜处方。结果见表7。 Since the liquid taste of this traditional Chinese medicine composition is bitter and difficult to swallow, and the tongue has an obvious thick feeling after swallowing, it is necessary to consider adding an appropriate amount of corrective agent to improve the mouthfeel of the preparation and improve the compliance of patients with medication. In the choice of flavoring agent, the taste was slightly worse after adding sucrose, honey, brown sugar, aspartame, etc., and finally stevioside was selected, and the dosage was screened after several people tasted it. In the end, adding 0.33% stevia was chosen as a more suitable prescription. The results are shown in Table 7.
表7 甜菊糖用量筛选结果 Table 7 Screening results of stevioside dosage
实验例6:防腐剂的筛选 Experimental Example 6: Screening of preservatives
为避免微生物污染引起变质、酸败等,中药提取液往往需加入适量防腐剂。苯甲酸钠无毒副作用,口感较好,为中药液体制剂的理想防腐剂。根据由苯甲酸钠作为防腐刘的常用剂量,经预试验确定其用量为0.30%。 In order to avoid deterioration and rancidity caused by microbial contamination, it is often necessary to add an appropriate amount of preservatives to the extract of traditional Chinese medicine. Sodium benzoate has no toxic and side effects, and has a good taste. It is an ideal preservative for traditional Chinese medicine liquid preparations. According to the usual dosage of sodium benzoate as antiseptic Liu, its dosage is determined to be 0.30% through preliminary tests.
实验例7:威灵仙所含主要成分的定性鉴别 Experimental Example 7: Qualitative identification of the main components contained in Clematis clematis
取本发明的中药组合物制剂2mL置于圆底烧饼中,加入2mol/L的HCl 30mL,水浴回流2小时,放凉后置于分液漏斗中,加入乙酸乙酯萃取3次,每次15mL,合并萃取液加压蒸干,甲醇定容至10mL,作为供试品溶液。 Take 2 mL of the Chinese medicine composition preparation of the present invention and place it in a round-bottomed sesame seed cake, add 30 mL of 2mol/L HCl, reflux in a water bath for 2 hours, put it in a separating funnel after cooling, add ethyl acetate to extract 3 times, 15 mL each time , The combined extracts were evaporated to dryness under pressure, and the volume was adjusted to 10 mL with methanol as the test solution.
另取齐墩果酸和常春藤皂常苷元对照品加甲醇制成每1mL含1mg,作为对照品溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各5μl,分别点于同一硅胶G薄层板上,以石油醚-乙酸乙酯-甲酸(10∶3∶0.1)为展开剂,薄层板置展开缸中预饱和30分钟,展开,取出,晾干,喷以10%硫酸乙醇溶液,在105℃加热至斑点显色清晰。供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的斑点。 Take another oleanolic acid and hedera saponin reference substance plus methanol to make each 1mL containing 1mg, as the reference solution. According to the thin-layer chromatography (Appendix VI B of "Chinese Pharmacopoeia" 2010 edition), draw 5 μl of each of the above two solutions, respectively spot on the same silica gel G thin-layer plate, and use petroleum ether-ethyl acetate-formic acid (10:3 : 0.1) as the developing agent, the thin-layer plate was placed in a developing cylinder and pre-saturated for 30 minutes, developed, taken out, dried in the air, sprayed with 10% sulfuric acid ethanol solution, and heated at 105°C until the spots were clearly colored. In the chromatogram of the test product, there are spots of the same color at the position corresponding to the chromatogram of the reference product.
实验例8:薄荷所含主要成分的鉴别 Experimental Example 8: Identification of main components contained in peppermint
取本发明的中药组合物制剂2mL置于分液漏斗中,加入石油醚萃取3次,每次5mL,合并乙醚,减压蒸干后加入2mL甲醇定容,作为供试品溶液。 Take 2 mL of the Chinese medicine composition preparation of the present invention and place it in a separatory funnel, add petroleum ether to extract 3 times, 5 mL each time, combine ether, evaporate to dryness under reduced pressure, add 2 mL of methanol to constant volume, as the test solution.
另取薄荷对照药材,粉碎过40目筛,取0.5g加10mL石油醚超声30min,过滤后,滤液蒸干并定容至1mL,作为对照药材溶液。 Take mint as a control medicinal material, crush it through a 40-mesh sieve, take 0.5 g and add 10 mL of petroleum ether to sonicate for 30 minutes, filter, evaporate the filtrate to dryness and dilute to 1 mL, and use it as the reference medicinal material solution.
另取薄荷醇对照品加甲醇制成每1ml含2mg,作为对照品溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各2μl,分别点于同一硅胶G薄层板上,以甲苯-乙酸乙酯(8∶18)为展开剂,预饱和30min后,展开,取出,晾干,喷以2%香草醛硫酸-乙醇(1∶4)显色剂,105℃加热至斑点显色清晰。供试品色谱中,在与对照品、对照药材色谱相应的位置上,显相同颜色的斑点。 Another menthol reference substance plus methanol made per 1ml containing 2mg, as the reference substance solution. According to the thin-layer chromatography (Appendix VI B of "Chinese Pharmacopoeia" 2010 edition), draw 2 μl of each of the above two solutions, respectively spot on the same silica gel G thin-layer plate, and develop with toluene-ethyl acetate (8:18) After pre-saturation for 30 minutes, develop, take out, dry in the air, spray with 2% vanillin sulfuric acid-ethanol (1:4) color developer, heat at 105°C until the spots are clear in color. In the chromatogram of the test product, there are spots of the same color at the positions corresponding to the chromatogram of the reference substance and the reference medicinal material.
实验例9:郁金所含主要成分的鉴别 Experimental Example 9: Identification of Main Components in Curcuma
取本发明中药组合物制剂2mL,加入无水乙醇25mL超声15min,滤过,减压回收溶剂,残渣用1mL乙醇溶解,作为供试品溶液。 Take 2mL of the Chinese medicine composition preparation of the present invention, add 25mL of absolute ethanol and sonicate for 15min, filter, recover the solvent under reduced pressure, and dissolve the residue with 1mL of ethanol as the test solution.
另取郁金对照药材,粉碎过40目筛,取2g,加25mL乙醇超声30min,过滤,定容至1mL作为对照药材溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各1-5μl,分别点于同一硅胶G薄层板上,以石油醚(60-90℃)-甲酸乙酯(15∶5)为展开剂,预饱和30min后,展开,取出晾干,喷以10%浓硫酸乙醇显色剂,105℃加热至斑点显色清晰。供试品色谱中,在与对照药材色谱相应的位置上,显相同颜色的斑点。 Take another curcuma reference medicinal material, crush it through a 40-mesh sieve, take 2 g, add 25 mL of ethanol to ultrasonic for 30 minutes, filter, and dilute to 1 mL as the reference medicinal material solution. According to the thin-layer chromatography (Appendix VI B of "Chinese Pharmacopoeia" 2010 edition), draw 1-5 μl of each of the above two solutions, respectively spot on the same silica gel G thin-layer plate, and use petroleum ether (60-90 ° C)-formic acid Ethyl ester (15:5) was used as the developing agent. After pre-saturation for 30 minutes, develop, take out and dry in the air, spray with 10% concentrated sulfuric acid ethanol color developer, and heat at 105°C until the spots are clearly colored. In the chromatogram of the test product, there are spots of the same color at the position corresponding to the chromatogram of the control medicinal material.
实验例10:石菖蒲所含主要成分的鉴别 Experimental Example 10: Identification of main components contained in Shichangpu
取本发明的中药组合物制剂5mL置于分液漏斗中,加入石油醚萃取3次,每次5mL,合并乙醚,减压蒸干后加入5mL甲醇定容,作为供试品溶液。 Get 5 mL of the Chinese medicine composition preparation of the present invention and place it in a separatory funnel, add petroleum ether to extract 3 times, 5 mL each time, combine ether, evaporate to dryness under reduced pressure, add 5 mL methanol to constant volume, as the test solution.
另取石菖蒲对照药材,粉碎过40目筛,取1g,加10mL乙醚超声30min,过滤后,滤液蒸干并定容至1mL,作为供试品溶液。 Another reference medicinal material, Shichangpu, was crushed through a 40-mesh sieve, and 1 g was taken, and 10 mL of ether was added for ultrasonication for 30 minutes. After filtration, the filtrate was evaporated to dryness and the volume was adjusted to 1 mL, as the test solution.
另取α-细辛醚对照品加甲醇制备成每mL含2mg,作为对照品溶液。照薄层色谱法(《中国药典》2010版附录VI B)试验,吸取上述两种溶液各1-5μl,分别点于同一硅胶G薄层板上,以石油醚(60-90℃)-乙酸乙酯(6∶4)为展开剂,预饱和30min后,展开,取出,晾干,置紫外光灯(365nm)下检视。供试品色谱中,在与对照品溶液色谱相应的位置上,显相同颜色的斑点。 Another α-asarone reference substance plus methanol prepared to contain 2mg per mL, as the reference substance solution. According to the thin-layer chromatography (Appendix VI B of "Chinese Pharmacopoeia" 2010 edition), draw 1-5 μl of each of the above two solutions, respectively spot on the same silica gel G thin-layer plate, and use petroleum ether (60-90 ℃)-acetic acid Ethyl ester (6:4) was used as the developer, pre-saturated for 30min, developed, taken out, dried in the air, and inspected under ultraviolet light (365nm). In the chromatogram of the test product, there are spots of the same color at the position corresponding to the chromatogram of the reference substance solution.
实验例11:中药组合物制剂中常春藤皂苷元、齐墩果酸含量测定实验 Experimental Example 11: Determination of Hedera Saponin and Oleanolic Acid Contents in Traditional Chinese Medicine Composition Preparations
检测波长的选择:取混合对照品溶液适量,在200-400nm波长进行紫外扫描,三个成分在205nm波长处有特征吸收,故选择205nm作为检测波长。 Selection of detection wavelength: take an appropriate amount of the mixed reference solution, and conduct ultraviolet scanning at a wavelength of 200-400nm. The three components have characteristic absorption at a wavelength of 205nm, so 205nm is selected as the detection wavelength.
色谱测定条件:乙腈(A)-0.1%磷酸(B),梯度洗脱(0~15min:70%A,15~20min:70%→90%A,20~30min:90%A,30~35:90%→70%);柱温30℃;流速1.0ml·min-1;进样量10uL;流速1ml/min,柱温30℃,理论塔板数按常春藤皂苷元、齐墩果酸计均不得低于1000。 Chromatographic determination conditions: acetonitrile (A)-0.1% phosphoric acid (B), gradient elution (0~15min: 70%A, 15~20min: 70%→90%A, 20~30min: 90%A, 30~35 : 90%→70%); column temperature 30°C; flow rate 1.0ml·min-1; The total shall not be less than 1000.
线性关系考察: Linear relationship investigation:
精密称取常春藤皂苷元、齐墩果酸对照品5.73mg,于25ml容量瓶中,色谱甲醇定容,分别精密吸取8ml,6ml,4ml,2ml,1ml,于10ml容量瓶中,色谱甲醇定容至刻度,过0.22μm有机滤膜,以10μl注入高效液相色谱仪按上述色谱条件测定峰面积,以峰面积积分值为纵坐标,分别以常春藤皂苷元、齐墩果酸进样量(ug)为横坐标,绘制标准曲线,计算得回归方程,结果见表8。 Accurately weigh 5.73 mg of hedera saponin and oleanolic acid reference substance, put it in a 25ml volumetric flask, and set it to volume with chromatographic methanol; Concentrate to the scale, pass through a 0.22 μm organic filter membrane, inject 10 μl into a high-performance liquid chromatograph to measure the peak area according to the above-mentioned chromatographic conditions, use the integral value of the peak area as the ordinate, and use the injection volume of hedera saponin and oleanolic acid respectively (ug) is the abscissa, draws the standard curve, calculates the regression equation, and the results are shown in Table 8.
表8 常春藤皂苷元、齐墩果酸线性关系考察 Table 8 Investigation of the linear relationship between hedera saponin and oleanolic acid
标准曲线:常春藤皂苷元Y=6E+0.6X+40997,R2=0.9999;标准曲线:齐墩果酸Y=6E+0.6X+61056,R2=0.9996; Standard curve: helexin Y=6E+0.6X+40997, R2=0.9999; standard curve: oleanolic acid Y=6E+0.6X+61056, R2=0.9996;
重现性试验: Reproducibility test:
精密吸取本发明的中药组合物制剂样品2ml,平行8份,分别加入2mol/L 30mlHCL,加热回流2h,放凉后转移至分液漏斗,用乙酸乙酯萃取5次,合并萃取液,回收溶剂,减压收干,残渣用色谱甲醇溶解,转移定容至10ml,过0.22μm有机滤膜,以10μl注入高效液相色谱仪按上述色谱条件测定峰面积。 Precisely draw 2ml of the Chinese medicine composition preparation sample of the present invention, parallel 8 parts, add 2mol/L 30ml HCL respectively, heat and reflux for 2h, let cool, transfer to a separatory funnel, extract 5 times with ethyl acetate, combine the extracts, and recover the solvent , dried under reduced pressure, the residue was dissolved in chromatographic methanol, transferred to a constant volume of 10ml, passed through a 0.22μm organic filter membrane, and 10μl was injected into a high performance liquid chromatograph to measure the peak area according to the above chromatographic conditions.
表9 常春藤皂苷元、齐墩果酸重复性考察 Table 9 Repeatability investigation of hedera saponin and oleanolic acid
结论:常春藤皂苷元、齐墩果酸的RSD值均小于5%,说明该方法重复性良好。 Conclusion: The RSD values of hedera saponin and oleanolic acid are less than 5%, indicating that the method has good repeatability.
精密度试验: Precision test:
精密吸取上述重现性实验样品8溶液10μL,重复进样6次,求得常春藤皂苷元、齐墩果酸峰面积相对标准偏差RSD<1%。结果见表10。 Precisely draw 10 μL of the above-mentioned reproducibility experiment sample 8 solution, repeat the injection 6 times, and obtain the relative standard deviation RSD of the peak areas of helexin and oleanolic acid<1%. The results are shown in Table 10.
表10 常春藤皂苷元精密度试验结果 Table 10 Helexin precision test results
稳定性试验 Stability test
精密吸取上述重现性实验样品10μL,分别于0,2,4,6,10,12进样1次,共进样6次,测定结果见表11,以常春藤皂苷元和齐墩果酸峰面积考察样品稳定性。 Precisely draw 10 μL of the above-mentioned reproducibility test sample, inject 1 sample at 0, 2, 4, 6, 10, 12 respectively, and inject 6 samples in total. The measurement results are shown in Table 11. Hederinin and oleanolic acid The peak area was used to test the stability of the sample.
表11 常春藤皂苷元、齐墩果酸稳定性试验 Table 11 Stability test of hedera saponin and oleanolic acid
结论:同一样品的常春藤皂苷元、齐墩果酸峰面积在12h内,RSD值小于1%,说明供试品溶液在12小时内稳定。 Conclusion: The peak areas of helexin and oleanolic acid of the same sample are within 12 hours, and the RSD value is less than 1%, indicating that the test solution is stable within 12 hours.
回收率试验: Recovery test:
按重复性考察结果,常春藤皂苷元的含量为0.90mg/ml;齐墩果酸含量为0.40mg/ml。因此,精密称取常春藤皂苷元9.40mg和齐墩果酸4.00mg于10ml容量瓶中,色谱甲醇定容,使其充分溶解,得混标溶液。 According to the repeated investigation results, the content of helexin was 0.90 mg/ml; the content of oleanolic acid was 0.40 mg/ml. Therefore, accurately weigh 9.40 mg of hedera saponin and 4.00 mg of oleanolic acid in a 10 ml volumetric flask, constant volume with methanol for chromatography, and fully dissolve them to obtain a mixed standard solution.
精密吸取上述混标溶液1ml于三角瓶,平行7份,加入精密吸取的1ml中试样品,加入2mol/L 30mlHCL,加热回流2h,放凉后转移至分液漏斗,用乙酸乙酯萃取5次,每次15ml,合并萃取液,减压收干溶剂,残渣用色谱甲醇溶解,定容至10ml,过0.22μm有机滤膜,以10μl注入高效液相色谱仪按上述色谱条件测定峰面积。 Accurately draw 1ml of the above mixed standard solution in the Erlenmeyer flask, parallel 7 parts, add 1ml of the pilot test sample precisely drawn, add 2mol/L 30ml HCL, heat and reflux for 2h, let cool, transfer to a separatory funnel, and extract with ethyl acetate for 5 Once, 15ml each time, combine the extracts, dry the solvent under reduced pressure, dissolve the residue with chromatographic methanol, set the volume to 10ml, pass through a 0.22μm organic filter membrane, inject 10μl into the high performance liquid chromatograph and measure the peak area according to the above chromatographic conditions.
按以下公式计算加样回收率: Calculate the sample recovery rate according to the following formula:
表12 常春藤皂苷元、齐墩果酸回收率 Table 12 Recovery rate of hedera saponin and oleanolic acid
结论:6份样品的加样回收率均在95%-105%之间,RSD值均小于5%,说明该方法稳定可靠,可以用于本发明中药组合物中常春藤皂苷元和齐墩果酸的含量测定。 Conclusion: the recovery rates of 6 samples are all between 95%-105%, and the RSD values are all less than 5%, which shows that the method is stable and reliable, and can be used for helexin and oleanolic acid in the Chinese medicine composition of the present invention content determination.
下面药效学实验结果用于进一步说明但不限于本发明。 The following pharmacodynamic experiment results are used to further illustrate but not limit the present invention.
实验例11:止咳药效实验观察 Experimental Example 11: Experimental observation on the efficacy of cough medicine
1、实验目的:通过氨水喷雾致咳试验,比较其止咳作用。 1. The purpose of the experiment: to compare the antitussive effects of ammonia water spray through the cough test.
2、实验材料 2. Experimental materials
2.1受试药物 止咳药的工艺一、工艺二、工艺三,由中国中医科学院中药研究所制剂中心提供,含量均为1.0g生药/ml。 2.1 Drugs under test Process 1, Process 2, and Process 3 of the cough medicine were provided by the Preparation Center of the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, and the contents were all 1.0 g crude drug/ml.
2.2动物 CD-1(ICR)小鼠,18-22g,由北京维通利华实验动物技术有限公司提供,合格证号为SCXK(京)2012-0001。 2.2 Animal CD-1 (ICR) mice, 18-22g, provided by Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., the certificate number is SCXK (Beijing) 2012-0001.
2.3试剂 氨水,国药集团化学试剂有限公司,批号:20120918。 2.3 Reagent Ammonia water, Sinopharm Chemical Reagent Co., Ltd., batch number: 20120918.
2.4仪器 402A超声雾化器,江苏鱼跃医疗设备有限公司出品。 2.4 Instrument 402A ultrasonic nebulizer, produced by Jiangsu Yuyue Medical Equipment Co., Ltd.
2.5动物分组 2.5 Animal grouping
取健康小鼠按体重随机分为10组,分别为模型对照组、实施例1药物高、中、低剂量组,实施例2的高、中、低剂量组、实施例3的高、中、低剂量组,每组10只,雌雄各半。 Get healthy mice and divide into 10 groups at random according to body weight, be respectively model control group, embodiment 1 drug high, middle and low dose groups, embodiment 2 high, middle and low dose groups, embodiment 3 high, middle and low dose groups Low-dose group, 10 rats in each group, half male and half male.
3、实验方法 3. Experimental method
采用氨水喷雾致咳法,实施例1、实施例2、实施例3药物分别以12.54、6.27、3.14g生药/kg灌胃给予小鼠,通过镇咳试验,比较其止咳作用。各组逐只灌胃给予相应药物,灌胃容积为20ml/kg,模型对照组灌胃给予相同容积的蒸馏水,给药后1小时,将小鼠逐只放入1000ml规格的玻璃烧杯中,上面加盖,雾化杯中盛入12.5%氨水40ml,送雾管连接雾化器与玻璃烧杯,以中度送风和最大送雾量的一定功率开机,喷雾5秒钟停止,观察并记录引起小鼠咳嗽所需时间(咳嗽潜伏期)及2分钟内咳嗽次数,以t检验进行组间比较。 Ammonia water spray was used to induce cough, and the drugs of Example 1, Example 2, and Example 3 were given to mice by intragastric administration of 12.54, 6.27, and 3.14 g of crude drug/kg, respectively, and their antitussive effects were compared through an antitussive test. Each group was intragastrically given the corresponding drug one by one, the volume of intragastric administration was 20ml/kg, and the model control group was intragastrically administered with the same volume of distilled water. One hour after the administration, the mice were put into a 1000ml glass beaker one by one. Cover it, put 40ml of 12.5% ammonia water into the atomizing cup, connect the atomizer and the glass beaker with the mist delivery pipe, turn on the machine with a certain power of moderate air supply and maximum mist delivery, stop spraying for 5 seconds, observe and record the cause The time required for mice to cough (cough latency) and the number of coughs within 2 minutes were compared between groups by t test.
4、实验结果 4. Experimental results
表13 氨水喷雾致小鼠咳嗽的影响 Table 13 The effect of ammonia water spray on coughing in mice
注:与对照组相比*P<0.05;**P<0.01 Note: Compared with the control group, *P<0.05; **P<0.01
5、止咳药效观察实验结论 5. Conclusions of the observation experiment on the efficacy of cough medicine
试验结果可见,本发明中药组合物实施例1的高、中、低三个剂量组以及实施例2、3的高、中剂量组均可明显延长小鼠咳嗽潜伏期;实施例1的高、中、低剂量组、实施例2的高剂量组以及实施例3的高、中剂量组均可明显减少小鼠咳嗽次数,与模型对照组相比具有显著性差异。 As seen from the test results, the high, middle and low dosage groups of Chinese medicine composition embodiment 1 of the present invention and the high and middle dosage groups of embodiments 2 and 3 all can obviously prolong the cough latency of mice; the high and middle dosage groups of embodiment 1 , low-dose group, the high-dose group of embodiment 2 and the high-dose and middle-dose groups of embodiment 3 can significantly reduce the number of mice coughing, compared with the model control group, there is a significant difference.
具体实施方式: detailed description:
实施例1:口服液的制备 Embodiment 1: the preparation of oral liquid
药材威灵仙300g、郁金250g、石菖蒲150g、薄荷150g,加入10倍水,以水蒸气蒸馏提取挥发油,8h后收集挥发油备用,将提油母液滤出,药渣加10倍量水煎煮1h,滤过,滤液与提油母液合并,以3500r/min离心20min,除去沉淀。浓缩后加95%乙醇使含醇量达65%,冷藏静置过夜后取出,滤过,滤液减压回收乙醇,加吐温80增溶挥发油,并与矫味剂(如蔗糖、蜂蜜、木糖醇、甜菊糖等一种或多种)、防腐剂(如山梨酸钠或钾盐、苯甲酸等一种或多种)以及药液混合均匀,定容至1000ml,灌装即得。 Medicinal materials Clematis 300g, Curcuma 250g, Shichangpu 150g, Peppermint 150g, add 10 times of water, extract volatile oil by steam distillation, collect volatile oil after 8 hours for later use, filter out the mother liquor of oil extraction, add 10 times of medicinal residue to decoct Boil for 1 hour, filter, combine the filtrate with oil extraction mother liquor, and centrifuge at 3500r/min for 20 minutes to remove the precipitate. After concentration, add 95% ethanol to make the alcohol content reach 65%, take it out after refrigerating and standing overnight, filter, and recover the ethanol from the filtrate under reduced pressure, add Tween 80 to solubilize the volatile oil, and mix it with correctives (such as sucrose, honey, wood One or more of sugar alcohol, stevia sugar, etc.), preservatives (such as one or more of sodium sorbate or potassium salt, benzoic acid, etc.) and liquid medicine are mixed evenly, and the volume is set to 1000ml, and the filling is ready.
实施例2:普通片剂的制备 Embodiment 2: the preparation of common tablet
药材威灵仙150g、郁金375g、石菖蒲150g、薄荷225g,加入10倍量水,以水蒸气蒸馏法提取挥发油,7小时收集挥发油备用,将提油母液滤出,药渣加入8倍量60%乙醇,回流2次,每次1h,醇提液合并,回收乙醇至无醇味,放置过夜后,抽滤将沉淀除去,浓缩至干,粉碎。挥发油用β环糊精包合,冷藏过夜,滤过,低温干燥,加入糊精、糖粉以及硬脂酸镁,与浸膏粉混匀,制粒,压制成1000片即得。 Medicinal materials Clematis 150g, Curcuma 375g, Shichangpu 150g, Peppermint 225g, add 10 times the amount of water, extract the volatile oil by steam distillation, collect the volatile oil for 7 hours for later use, filter out the mother liquor of oil extraction, add 8 times the amount of medicinal residue 60% ethanol, reflux twice, 1 hour each time, combine the ethanol extracts, recover the ethanol until it has no alcohol smell, after standing overnight, remove the precipitate by suction filtration, concentrate to dryness, and pulverize. The volatile oil is clathrated with β-cyclodextrin, refrigerated overnight, filtered, dried at low temperature, added with dextrin, powdered sugar and magnesium stearate, mixed with extract powder, granulated, and pressed into 1000 tablets.
实施例3:喷雾剂的制备 Embodiment 3: the preparation of spray
药材石菖蒲225g、薄荷75g加入14倍水,以水蒸气蒸馏法提取挥发油,7小时收集挥发油备用,将提油母液滤出,药渣加10倍水,煎煮1小时,将煎煮液过滤后与提油母液合并,以3500r/min离心20min除去沉淀,上清液浓缩后加95%乙醇使含醇量达65%,冷藏静置过夜后取出,滤过,滤液减压回收乙醇,冷藏备用。 Add 225g of medicinal materials Acorus calamus and 75g of mint with 14 times of water, extract the volatile oil by steam distillation, collect the volatile oil for 7 hours for later use, filter out the oil extraction mother liquor, add 10 times of water to the medicinal residue, decoct for 1 hour, and filter the decoction Afterwards, it was combined with the oil extraction mother liquor, and the precipitate was removed by centrifugation at 3500r/min for 20min. After the supernatant was concentrated, 95% ethanol was added to make the alcohol content reach 65%. spare.
威灵仙375g、郁金300g加入6倍量70%乙醇,回流两次,每次1h,合并醇提液,回收乙醇。并与石菖蒲、薄荷水提醇沉后药液合并,减压浓缩。加吐温80增溶挥发油后与药液混合均匀,定容至1000ml,灌装即得 Add 6 times the amount of 70% ethanol to 375 g of Clematis clematis and 300 g of turmeric, reflux twice for 1 hour each time, combine the ethanol extracts, and recover ethanol. And combined with the medicinal solution after water extraction and alcohol precipitation of Shichangpu and peppermint, and concentrated under reduced pressure. Add Tween 80 to solubilize the volatile oil, mix it evenly with the liquid medicine, set the volume to 1000ml, and fill it.
实施例4:喷雾剂的制备 Embodiment 4: the preparation of spray
威灵仙500g、郁金375g、石菖蒲75g、薄荷225g,加10倍量70%乙醇回流提取3次,每次3小时,提取液合并,过滤,滤液加0.05%尼泊金乙酯、1.5%甜菊糖,定容至1000ml,分装于喷雾瓶中,灭菌即得。 Clematis 500g, Curcuma 375g, Shichangpu 75g, Peppermint 225g, add 10 times the amount of 70% ethanol to reflux extraction 3 times, each time for 3 hours, the extracts are combined, filtered, the filtrate is added with 0.05% ethyl paraben, 1.5 % stevioside, fixed to 1000ml, distributed in spray bottles, and sterilized.
实施例5:口含片的制备 Embodiment 5: the preparation of buccal tablet
药材威灵仙150g、郁金375g、石菖蒲150g、薄荷225g,加入10倍量水,以水蒸气蒸馏法提取挥发油,7小时收集挥发油,用少量乙醇溶解备用;将提油母液滤出,药渣加入8倍量60%乙醇,回流2次,每次1h,醇提液合并,回收乙醇至无醇味,得浓缩液,加入适量甘露醇、阿斯巴甜、硬脂酸镁以及挥发油乙醇溶液,混匀,制粒,压制成1000片即得。 Medicinal materials Clematis 150g, Curcuma 375g, Shichangpu 150g, Peppermint 225g, add 10 times the amount of water, extract the volatile oil by steam distillation, collect the volatile oil in 7 hours, dissolve it with a small amount of ethanol for later use; Add 8 times the amount of 60% ethanol to the residue, reflux twice, 1 hour each time, combine the ethanol extracts, recover the ethanol until it has no alcohol smell, and obtain a concentrated solution, add appropriate amount of mannitol, aspartame, magnesium stearate and volatile oil ethanol solution, mixed evenly, granulated, and compressed into 1000 tablets.
实施例6:中药发明组合物的应用1 Embodiment 6: Application 1 of Chinese medicine invention composition
威灵仙500g、郁金375g、石菖蒲75g、薄荷225g,糊精110g,微粉硅胶15g,制成胶囊1000粒,用于各种急慢性咳嗽的治疗。 Clematis 500g, turmeric 375g, calamus 75g, mint 225g, dextrin 110g, micronized silica gel 15g, made into 1000 capsules, used for the treatment of various acute and chronic coughs.
实施例7:中药发明组合物的应用2 Embodiment 7: Application 2 of the invention composition of traditional Chinese medicine
药材威灵仙300g、郁金250g、石菖蒲150g、薄荷150g,蔗糖90g,甜菊糖5g,苯甲酸10g,制成口服液1000ml,用于感染性咳嗽的治疗。 Medicinal materials Clematis 300g, Curcuma 250g, Shichangpu 150g, Peppermint 150g, sucrose 90g, stevioside 5g, benzoic acid 10g, make oral liquid 1000ml, for the treatment of infectious cough.
Claims (25)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510708038.9A CN106620498A (en) | 2015-10-28 | 2015-10-28 | Preparation method, quality control and use of traditional Chinese medicine composition for treating postinfectious cough |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510708038.9A CN106620498A (en) | 2015-10-28 | 2015-10-28 | Preparation method, quality control and use of traditional Chinese medicine composition for treating postinfectious cough |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106620498A true CN106620498A (en) | 2017-05-10 |
Family
ID=58815575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510708038.9A Pending CN106620498A (en) | 2015-10-28 | 2015-10-28 | Preparation method, quality control and use of traditional Chinese medicine composition for treating postinfectious cough |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106620498A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110967440A (en) * | 2018-09-28 | 2020-04-07 | 九芝堂股份有限公司 | Method for identifying belvedere fruit in oral liquid containing donkey-hide gelatin, pearl essence and blood |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090311350A1 (en) * | 2004-03-23 | 2009-12-17 | Lifeline Nutraceuticals Corporation | Compositions for alleviating inflammation and oxidative stress in a mammal |
-
2015
- 2015-10-28 CN CN201510708038.9A patent/CN106620498A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090311350A1 (en) * | 2004-03-23 | 2009-12-17 | Lifeline Nutraceuticals Corporation | Compositions for alleviating inflammation and oxidative stress in a mammal |
Non-Patent Citations (6)
| Title |
|---|
| 傅超美: "《中药药剂学实验》", 28 February 2015, 中国中医药出版社 * |
| 国家药典委员会: "《中华人民共和国药典:2015版,一部》", 30 June 2015, 中国医药科技出版社 * |
| 夏征农: "《辞海医药卫生分册》", 31 March 1989, 上海辞书出版社 * |
| 张海丰: "《威灵仙的研究》", 31 October 2013, 吉林大学出版社 * |
| 李佳: "中药威灵仙的化学成分及药理作用研究", 《特产研究》 * |
| 李倩倩: "不同品种威灵仙药材的质量研究", 《中国优秀硕士学位论文数据库医药卫生科技辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110967440A (en) * | 2018-09-28 | 2020-04-07 | 九芝堂股份有限公司 | Method for identifying belvedere fruit in oral liquid containing donkey-hide gelatin, pearl essence and blood |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023532621A (en) | Antibacterial antiviral pharmaceutical composition and use thereof | |
| CN111407877A (en) | Traditional Chinese medicine composition, preparation method, detection method and use for treating novel coronavirus pneumonia | |
| CN102579860B (en) | Child medicament extract composition and preparation method and application thereof | |
| CN104758515A (en) | Traditional Chinese medicinal composition for treating nephropathy as well as preparation method and detection method thereof | |
| CN101361795B (en) | A kind of pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102861255B (en) | A kind ofly treat the medicine of influenza and the preparation method of preparation thereof and method of quality control | |
| CN102908519B (en) | A kind ofly treat the medicine of influenza and the preparation method of preparation thereof and quality determining method | |
| CN111249421B (en) | Traditional Chinese medicine preparation for treating initial damp-heat exogenous fever as well as preparation method and application thereof | |
| CN104998071A (en) | Compound preparation ofherb of dense flower Bulbophyllum and preparation and detection method for said compound preparation | |
| CN106620498A (en) | Preparation method, quality control and use of traditional Chinese medicine composition for treating postinfectious cough | |
| CN101670088B (en) | Traditional Chinese medicine composite for treating acute/chronic bronchitis | |
| CN102335132A (en) | Asarin inhalation aerosol and preparation method thereof | |
| CN100415255C (en) | A kind of traditional Chinese medicine composition and preparation method thereof | |
| CN100553660C (en) | A kind of pharmaceutical composition and preparation method thereof | |
| CN104402897B (en) | Method for extracting high purity asarinin by supercritical carbon dioxide extraction method and application thereof | |
| CN116570669A (en) | Method for treating diseases and traditional Chinese medicine composition used | |
| CN107243024B (en) | A kind of double golden pharmaceutical compositions connected, a kind of Neulized inhalation solution of double gold even and its preparation method and application | |
| Guo et al. | Fast onset of action and the analgesic and sedative efficacy of essential oil from Rhizoma Chuanxiong after nasal administration | |
| CN102451442A (en) | A kind of extraction process of antidepressant traditional Chinese medicine | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| WO2005077393A1 (en) | Herbal formulation comprising extracts of adhatoda, hedychium and curcuma as cough syrup | |
| CN100391491C (en) | A kind of pharmaceutical composition for treating cardiovascular disease and its preparation method | |
| CN100435817C (en) | A Chinese medicinal composition for treating respiratory system diseases, and its preparation method | |
| CN100509049C (en) | A kind of content determination method of compound traditional Chinese medicine | |
| CN101041000B (en) | A kind of pharmaceutical composition for treating snoring and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Hui Document name: Deemed as a notice of withdrawal |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170510 |